BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nanobac Life Sciences, Inc. Release: Prominent Research Studies Link Nanobacteria Infection To Urological Diseases


10/19/2005 5:13:03 PM

TAMPA, Fla.--(BUSINESS WIRE)--March 16, 2005--Nanobac Life Sciences, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") informs that researchers have described a relationship between Nanobacteria and urological disorders such as prostatitis, kidney stones, and Polycystic Kidney Disease (PKD). Until these studies, no single infection, viral or bacterial had been indicated that could have promoted these disease processes. Because of the debilitating nature of these urological diseases, and the Company's belief that Nanobacteria might play a key role in their development, Nanobac has focused its efforts on investigating the relationship between Nanobacteria and these diseases. This release is intended to summarize what has been determined thus far, and what remains to be done. A recent observational study of prostatitis patients, lead by Daniel A. Shoskes, M.D., of Cleveland Clinic Florida, demonstrated a significant improvement in the symptoms of chronic prostatitis/chronic pelvic pain syndrome for those patients who took 3 months of Nanobac's comET nanobiotic regimen, a patented therapeutic method comprised of a nutriceutical (Nanobac Oral Supplement, Nanobac Sciences, Tampa, FL), EDTA (Calcium Disodium EDTA Suppository (Nanobac Sciences, Tampa, FL) and tetracycline. The treated group of fifteen patients had prostatic stones and longstanding Chronic Pelvic Pain Syndrome (CPPS) symptoms unresponsive to multiple prior conventional therapies. The treatment is designed to eliminate stone forming Nanobacteria and the study found that 80% had a significant improvement in symptoms after 3 months. Two patients who had been on complete medical disability have returned to work.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES